ⓘ Enfortumab vedotin

                                     

ⓘ Enfortumab vedotin

Enfortumab vedotin is an antibody-drug conjugate designed for the treatment of cancer expressing Nectin-4. Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug and the linker.

The most common side effects are fatigue, peripheral neuropathy nerve damage that causes tingling or numbness, loss of appetite, rash, alopecia hair loss, nausea, change of taste, diarrhea, dry eyes, Itching and dry skin.

Fully humanized antibodies were created by scientists at Agensys Astellas part using Xenomice from Amgen, technology binding and holding the antibody and toxin together, and was licensed from Seattle genetics.

The results of phase I clinical trial was recorded in 2016.